[The therapy of the early ovarian cancer (T1/T2 M0 N0) (author's transl)].
The paper deals with the results of a randomized prospective therapeutic study concerning 60 patients with ovarian cancers in stages T1 M0 N0 and T2 M0 N0 without (A group) and with (B group) postoperative chemotherapy, who had been operated on under a curative objective. The operative approach covered the abdominal exstirpation of the uterus with both adnexa and resection of the omentum. In stage T1 M0 N0 the 5-year survival time was reached by 94% of the patients without follow-up treatment (A group) and 90% of those who received such treatment (B group). In stage T2 M0 N0 all the patients without follow-up treatment (A group) and 76% of those cytostatically treated (B group) survived 5 years. While after a 10-year observation period the therapeutic results have remainded unchanged for stage T2 M0 N0 the survival rate of patients with tumours in stage T1 M0 N0 who hat received follow-up treatment has decreased to 62%. Statistical comparison of therapeutic concepts was not significant (error probability 5%). Attention is drawn to the importance of the operative approach. Ruptured secondura ovarian cancers and ascites do not anymore permit the curative approach and drastically reduce the chances of survival. Present methods of follow-up treatment cannot improve the effectiveness of the curatively performed operative measures take in case of ovarian cancer 5 of stages T1 M0 N0 and T2 M0 N0.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002369:Castration; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D011379:Prognosis
D000970:Antineoplastic Agents
Zur Therapie des Ovarialkariznos im lokal begrenzten Stadium T1/T2 M0 N0.